Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
18 hedge funds and large institutions have $7.28M invested in Biolase, Inc. in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
20% more funds holding
Funds holding: 15 → 18 (+3)
51% less capital invested
Capital invested by funds: $14.9M → $7.28M (-$7.58M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Archon Capital Management
Seattle,
Washington
|
+$536K |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$42K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$16.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$16.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$316K |
| 2 |
BC
Birchview Capital
Burlington,
Vermont
|
-$83K |
| 3 |
VF
Virtu Financial
New York
|
-$27K |
| 4 |
TFO
Tarbox Family Office
Newport Beach,
California
|
-$9.69K |
| 5 |
Morgan Stanley
New York
|
-$3.23K |
BIOL Hedge Fund Activity: Q4 2018 in Review
18 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2018, worth a combined $7.28M — down 51% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BIOL positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Archon Capital Management, opening a new position worth an estimated $536K. The largest seller was Vanguard Group, cutting an estimated $316K.
- 18 institutional investors held Biolase, Inc. (BIOL) as of Q4 2018, up from 15 in Q3 2018.
- Funds reported $7.28M of Biolase, Inc. stock for Q4 2018, down 51% quarter-over-quarter.
- 5 funds opened new Biolase, Inc. positions in Q4 2018 and 2 closed out, a net change of +3 holders.
- The largest Biolase, Inc. buyer in Q4 2018 was Archon Capital Management, an estimated $536K added.
- The largest Biolase, Inc. seller in Q4 2018 was Vanguard Group, an estimated $316K sold.
Based on aggregated 13F filings for Q4 2018.